Glaukos
Glaukos Corporation is an ophthalmic medical technology company based in San Clemente, California. Founded in 1998, Glaukos focuses on developing and commercializing innovative therapies for glaucoma and other eye conditions. The company aims to enhance the standard of care in the ophthalmic market through its advanced technologies. Glaukos specializes in micro-invasive glaucoma surgery (MIGS) technologies, which improve treatment outcomes with minimally invasive solutions. Its notable products include the iStent family, featuring the iStent inject W for enhancing aqueous outflow, the iStent Infinite for advanced glaucoma management, and the iDose TR, a sustained-release implant for intraocular pressure reduction. The company actively invests in research and development, with significant funding directed towards clinical trials and new medical devices.
Work at Glaukos in HR or recruiting? Claim this page
Headcount trend
Glaukos went from 626 employees in Jul 2023 to 735 in Jun 2025. Jan to Jun 2025: 47 people joined, 12 left.
Headcount data through Jun 2025
Org structure
Headcount by department
Executive compensation
Hiring now
See all jobsH-1B sponsorship
The department split adds up all the years listed above. FY2026 alone: 6 filings.
Peer reviews
Worked with someone at Glaukos?
Anonymous peer reviews on OffTheRecord
Similar companies
Glaukos FAQ
How many employees does Glaukos have?
Glaukos has about 735 employees, up 1.4% over the 3 months to Jun 2025.
Does Glaukos sponsor H1B visas?
Yes. Glaukos filed 6 H1B (LCA) applications in FY2026, according to the latest U.S. Department of Labor disclosures. Most of them were for Engineering roles.
What is Glaukos's revenue per employee?
Glaukos makes about $550K in revenue per employee, based on $404.52M annual revenue and 735 employees.
Is Glaukos a public company?
Yes. Glaukos is publicly traded under the ticker GKOS on NASDAQ.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.
